2-Methoxy-1,2,3,3a,4,5,6,6a-octahydropentalene

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Methoxy-1,2,3,3a,4,5,6,6a-octahydropentalene
• 英文别名: 2-methoxy-1,2,3,3a,4,5,6,6a-octahydropentalene
• 化学式: C₉H₁₆O
• 分子量: 140.22
• InChiKey: IGEMCXFLTYRPKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• C-GLYCOSIDE DERIVATIVES
  申请人：Xuanzhu Pharma Co., Ltd.

  公开号：EP2725031A1

  公开（公告）日：2014-04-30

  The present invention involves a compound represented by general formula (I), a derivative thereof and a use thereof: wherein R1, R2, R3, R4, R5a, R5b, R5c and X are defined as in the description.

  本发明涉及通式 (I) 所代表的化合物、其衍生物及其用途： 其中 R1、R2、R3、R4、R5a、R5b、R5c 和 X 的定义如说明书所述。
• [EN] COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR<br/>[FR] COMPOSÉ AYANT UNE ACTIVITÉ DE DÉGRADATION DE LA KINASE BTK, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION PHARMACEUTIQUE<br/>[ZH] 一种具有降解BTK激酶的化合物及其制备方法和药学上的应用
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2022007824A1

  公开（公告）日：2022-01-13

  本发明涉及一种通式(I)所述的化合物或者其立体异构体、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶，及其中间体和制备方法，以及在BTK相关疾病如肿瘤或自身免疫系统疾病中的用途。 B-L-K (I)
• C-GLYCOSIDE DERIVATIVE
  申请人：XUANZHU PHARMA CO., LTD.

  公开号：US20170101388A1

  公开（公告）日：2017-04-13

  The present invention involves a compound represented by general formula (I), a derivative thereof and a use thereof: wherein R 1 , R 2 , R 3 , R 4 , R 5a , R 5b , R 5c and X are defined as in the description.
• AMINO PRYAN RING DERIVATIVE AND COMPOSITION AND USE THEREOF
  申请人：Sichuan Haisco Pharmaceutical Co., Ltd.

  公开号：US20170121338A1

  公开（公告）日：2017-05-04

  The present disclosure relates to an amino pyran ring derivative and a composition and use thereof, and in particular, to an amino pyran ring derivative represented by general formula (I) or a stereoisomer, a pharmaceutically acceptable salt or a prodrug thereof, a pharmaceutical composition comprising the derivative, and their medical use in the manufacture of a di-peptidyl peptidase IV (DPP-IV) inhibitor, in formula (I) the substituents are defined the same as those in the specification.